一个空间层次网络学习框架用于药物重新定位,允许从宏观到微观规模的解释
Zhonghao Ren1, Xiangxiang Zeng1, Yizhen Lao1
1College of Computer Science and Electronic Engineering, Hunan University, Changsha, China.
Communications biology
|October 31, 2024
概括
这项研究介绍了SpHN-VDA,这是一种用于药物重新定位的新框架,它集成了分子3D结构和生物网络. 它准确地识别了潜在的候选药物,并增强了病毒与药物相关性的预测.
科学领域:
- 生物医学网络学习学习
- 计算机化药物发现.
- 药理学建模 药理学建模
背景情况:
- 传统的网络架构难以将分子结构与生物医学网络联系起来.
- 当前的方法在捕获远程依赖和复杂的生物信息方面面临挑战.
研究的目的:
- 开发一个新的框架,SpHN-VDA,用于增强药物重新定位和病毒药物关联识别.
- 将分子3D结构和生物关联建成一个统一的网络.
主要方法:
- 介绍空间层次网络 (SpHN) 用于建模分子3D结构和生物关联.
- 开发一个端到端的框架,SpHN-VDA,使用三重注意力机制.
- 整合空间层次信息,以提高机器对分子功能的理解.
主要成果:
- 在三个数据集中,SpHN-VDA的表现优于领先的模型,特别是在分布外和冷启动场景中.
- 证明了对数据干扰的增强稳定性 (20-40%).
- 通过与SARS-CoV-2尖端蛋白分子对接确定了25种潜在的候选药物,并验证了预测.
结论:
- SpHN-VDA有效地增强了药物重新定位和病毒与药物关联的识别.
- 该框架准确地识别了关键结合部位的动图,没有蛋白质残留的注释.
- 这项研究表明,SpHN-VDA在发现各种疾病的有效治疗中具有显著的潜力.
相关概念视频
Analysis of Population Pharmacokinetic Data
235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Structure-Activity Relationships and Drug Design
622
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
622
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
60
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
60
Pharmacokinetic Models: Overview
600
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
600
Quantitative Aspects of Drug-Receptor Interaction
937
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
937
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
32
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
32


